Clinical Data Pepaxti study supports use in wider myeloma population PharmaTimesPhase 2 bridge data show consistent outcomes in patients with impaired kidney functionOncologyRead full story pharminent May 20, 2026 (Last updated: May 21, 2026) PharmaTimes Phase 2 bridge data show consistent outcomes in patients with impaired kidney function Oncology Read full story Post navigation Previous: Beam one-ups Wave as both show promise of genetic editing for AATDNext: Pazdur declines to announce candidacy for vacated FDA commissioner role Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
